Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
被引用次数：47 相关文章

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma… - Medical oncology …, 2013 - pubmed.ncbi.nlm.nih.gov
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.

T Yoshida, K Yamada, K Azuma… - Medical …, 2013 - search.ebscohost.com
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.

T Yoshida, K Yamada, K Azuma… - Medical Oncology …, 2012 - europepmc.org
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical Oncology, 2013 - infona.pl
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma, A Kawahara… - Medical …, 2013 - search.proquest.com
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
[PDF] psu.edu

[PDF][PDF] Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Med Oncol, 2013 - Citeseer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

[引用][C] Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical …, 2012 - cir.nii.ac.jp
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with
non-small-cell lung cancer: a retrospective analysis | CiNii Research CiNii 国立情報学研究所 …

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.

T Yoshida, K Yamada, K Azuma… - Medical …, 2013 - search.ebscohost.com
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

[引用][C] Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer